SynthesisTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2014
Genetic polymorphism of DNA methyltransferase 3B 149 C>T and risk of colorectal cancer: a meta-analysis.
Synthesis in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.
- Systematic evaluation of cancer risk associated with DNMT3B polymorphisms.Journal of cancer research and clinical oncology · 2015Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Numerous studies have investigated the risk of colorectal cancer (CRC) associated with the polymorphism of DNA methyltransferase 3B (DNMT3B) 149 C>T, but results have been inconsistent. We performed this meta-analysis to drive a more precise estimation of the association between this polymorphism and risk of CRC. A comprehensive search was conducted to identify all case-control studies of the -149C>T polymorphism of DNMT3B and CRC risk. A total of seven eligible studies, including 2,666 cases and 4,022 controls, relating the DNMT3B polymorphism of -149C>T to the risk of CRC were identified. It suggested no significant associations between -149C>T polymorphism of DNMT3B gene and the risk of developing CRC in the recessive, dominant, and co-dominant models (for CC versus TT: OR = 0.90, 95% CI = 0.90-1.25, P heterogeneity = 0.37; for recessive model: OR = 0.54, 95% CI = 0.28-1.04, P heterogeneity = 0.00001; for dominant model: OR = 1.07, 95% CI = 0.93-1.23, P heterogeneity = 0.83; and for C allele versus T allele: OR = 0.70, 95% CI = 0.43-1.13, P heterogeneity = 0.00001). In the subgroup analysis, there is no significant associations were also found in European populations (for CC versus TT: OR = 1.09, 95% CI = 0.92-1.30, P heterogeneity = 0.88; for recessive model: OR = 1.00, 95% CI = 0.88-1.13, P heterogeneity = 0.14; for dominant model: OR = 1.50, 95% CI = 0.89-2.54, P heterogeneity = 0.00001; and for C allele versus T allele: OR = 0.70, 95% CI = 0.38-1.28, P heterogeneity = 0.00001). In conclusion, no significant association was found between the -149C>T polymorphisms in DNMT3B and CRC susceptibility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.